Latest News
Fenebrutinib Approval: When Could the FDA Decide on Roche’s MS Drug?
Fenebrutinib approval is now under US priority review, but Roche has not said when the FDA will decide. The company announced on 30 September 2026 that the agency had accepted its new drug application. The filing covers relapsing multiple sclerosis (RMS) and primary...
Latest News
Avacopan UK Suspension Follows Retracted Trial Data
The avacopan UK suspension took effect on 1 September 2026. The Medicines and Healthcare products Regulatory Agency stopped supply of the medicine to new patients that day. It also signalled its intention to revoke the UK marketing authorisation on 1 March 2027. The...
Midlife Metabolic Change: How Behaviour, Nutrition and Stress Shape Health
Midlife marks one of the most significant physiological transitions in the human lifespan. For many individuals, particularly those navigating perimenopause and menopause, metabolic stability becomes harder to maintain, appetite signals shift, energy becomes less...
UK Animal Testing Deadline: What December Actually Requires
The UK animal testing deadline that matters most falls at the end of December. By then, regulatory testing on animals for skin irritation, eye irritation and skin sensitisation is meant to stop. It is the largest of a cluster of targets the Replacing Animals in...
AI in IVF: Ethical and Legal Limits of Algorithmic Decision-Making
AI embryo selection tools can support clinical judgment, but current evidence does not justify treating an algorithmic score as a clinical verdict. A prediction is not a decision Artificial intelligence is entering in vitro fertilisation at one of its most...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
FDA Approves Commercial Manufacturing at Rezon Bio
Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar. This milestone represents an important step in the continued development of Rezon Bio's...
Doctors Warn AI Diet Advice Should Not Replace Medical Care
As more people turn to AI tools and online algorithms for diet and weight-loss advice, doctors are warning that this growing reliance may be overlooking critical health risks. Doctors stress that AI-generated information should never replace personalised medical...
Fertility Decisions and AI: Clarity Without False Certainty
As a researcher studying how people interact with large language models (LLMs), and as a clinician trained at the master’s level in clinical psychology, I keep seeing the same pattern in fertility and reproductive contexts. People rarely turn to AI only for...
Uniphar | Clinical merges with BMclinical
Leading global healthcare services provider Uniphar announces a strategic merger between Uniphar | Clinical and BMclinical, reinforcing Uniphar | Clinical’s integrated clinical supply offering and solidifying its position as a trusted partner to pharmaceutical and...
AI-Enabled Pathology: De-risking Oncology Drug Development
Today, oncology drug development continues to experience the highest attrition rates across therapeutic areas[1]. Despite major advances in molecular profiling and biomarker-driven strategies, a significant proportion of oncology clinical trials still fail, often due...
Why Sugar May Matter More Than We Thought
A New Energy-Centered Model of Metabolic Disease For decades, sugar has been framed as a problem of excess. Too many calories. Too many insulin spikes. Too much sweetness in the modern diet. That framing has shaped public health guidance, food reformulation, and...
Cera and Promptly Health Partner to Bridge the ‘Evidence Gap’
Cera, Europe’s largest digital-first home healthcare provider, has announced a global real-world evidence (RWE) partnership with Promptly Health, focused on the over-65s, to accelerate drug development and enable precision medicine. The partnership integrates Cera’s...
From Hype to Hard Science: Unlocking MSC Therapy’s Promise
After decades of promise and setbacks, advanced manufacturing platforms and robust Phase 2/3 trials are demonstrating whether MSCs can deliver transformative treatments for high-burden diseases Mesenchymal stromal cells (MSCs) have been called the most promising...
RCM Efficiency: Solving Insurance Denials & Margin Pressure
Insurance Denials and Revenue Cycle Inefficiencies Are Becoming a Primary Driver of Hospital Financial Strain U.S. hospitals are entering the next fiscal cycle under sustained financial pressure, and insurance denials have emerged as one of the most consequential, yet...
Thousands Recruited for “New Era” Severe Mental Illness Study
Thousands of people living with schizophrenia and severe depression are being recruited by the NHS for a major new study which could unlock a “new era” of personalised treatment for severe mental illness. As part of the world’s largest mental health study, researchers...
THX Pharma and Biocodex Sign Licensing Deal for Batten-1 and TX01 Therapies
THX Pharma (formerly known as Theranexus) has entered into a strategic licensing agreement with French pharmaceutical company Biocodex covering two experimental programs, Batten-1 and TX01, in a move aimed at accelerating development and expanding commercial reach....
Chronic Pain and Neuroplastic Pain: Rethinking How Pain is Created
Chronic pain affects hundreds of millions of people worldwide and remains one of the most challenging problems in modern medicine. For decades, pain has largely been understood as a direct signal of tissue damage or disease. However, advances in pain science are...
FDA Approves Commercial Manufacturing at Rezon Bio
Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar. This milestone represents an important step in the continued development of Rezon Bio's...
Doctors Warn AI Diet Advice Should Not Replace Medical Care
As more people turn to AI tools and online algorithms for diet and weight-loss advice, doctors are warning that this growing reliance may be overlooking critical health risks. Doctors stress that AI-generated information should never replace personalised medical...
Fertility Decisions and AI: Clarity Without False Certainty
As a researcher studying how people interact with large language models (LLMs), and as a clinician trained at the master’s level in clinical psychology, I keep seeing the same pattern in fertility and reproductive contexts. People rarely turn to AI only for...
Uniphar | Clinical merges with BMclinical
Leading global healthcare services provider Uniphar announces a strategic merger between Uniphar | Clinical and BMclinical, reinforcing Uniphar | Clinical’s integrated clinical supply offering and solidifying its position as a trusted partner to pharmaceutical and...
AI-Enabled Pathology: De-risking Oncology Drug Development
Today, oncology drug development continues to experience the highest attrition rates across therapeutic areas[1]. Despite major advances in molecular profiling and biomarker-driven strategies, a significant proportion of oncology clinical trials still fail, often due...
Why Sugar May Matter More Than We Thought
A New Energy-Centered Model of Metabolic Disease For decades, sugar has been framed as a problem of excess. Too many calories. Too many insulin spikes. Too much sweetness in the modern diet. That framing has shaped public health guidance, food reformulation, and...
Cera and Promptly Health Partner to Bridge the ‘Evidence Gap’
Cera, Europe’s largest digital-first home healthcare provider, has announced a global real-world evidence (RWE) partnership with Promptly Health, focused on the over-65s, to accelerate drug development and enable precision medicine. The partnership integrates Cera’s...
From Hype to Hard Science: Unlocking MSC Therapy’s Promise
After decades of promise and setbacks, advanced manufacturing platforms and robust Phase 2/3 trials are demonstrating whether MSCs can deliver transformative treatments for high-burden diseases Mesenchymal stromal cells (MSCs) have been called the most promising...
RCM Efficiency: Solving Insurance Denials & Margin Pressure
Insurance Denials and Revenue Cycle Inefficiencies Are Becoming a Primary Driver of Hospital Financial Strain U.S. hospitals are entering the next fiscal cycle under sustained financial pressure, and insurance denials have emerged as one of the most consequential, yet...
Thousands Recruited for “New Era” Severe Mental Illness Study
Thousands of people living with schizophrenia and severe depression are being recruited by the NHS for a major new study which could unlock a “new era” of personalised treatment for severe mental illness. As part of the world’s largest mental health study, researchers...
THX Pharma and Biocodex Sign Licensing Deal for Batten-1 and TX01 Therapies
THX Pharma (formerly known as Theranexus) has entered into a strategic licensing agreement with French pharmaceutical company Biocodex covering two experimental programs, Batten-1 and TX01, in a move aimed at accelerating development and expanding commercial reach....
Chronic Pain and Neuroplastic Pain: Rethinking How Pain is Created
Chronic pain affects hundreds of millions of people worldwide and remains one of the most challenging problems in modern medicine. For decades, pain has largely been understood as a direct signal of tissue damage or disease. However, advances in pain science are...
Featured Articles
Further News
Beyond Hallucinated Binders: The Enzymatic Frontier for Generative AI
Generative AI has already changed what is possible in protein engineering. In the last few years, the field has moved from predicting protein structures to proposing entirely new proteins, often with experimentally verified folding and binding, at a pace that was...
Neuroscience of Trauma, Stress & Alcohol: Integrated Treatment
Alcohol problems are often framed as a failure of willpower or “poor lifestyle choices”. Yet clinical neuroscience has made that narrative increasingly untenable. Problematic alcohol use is often a learned response to stress, a learned neurobiological adaptation,...
Auxilium and MBI Launch Life Sciences Accelerator Cohort in Worcester
Auxilium and Massachusetts Biomedical Initiatives (MBI) have announced a joint life sciences accelerator cohort in Worcester designed to attract and support founders developing the next generation of healthcare and life sciences technologies. Founders selected for the...
Experimental Alzheimer’s Pill Boosts the Brain’s Cleanup System
Wouldn’t life be easier if someone was there to keep on top of chores around the house? That’s the idea behind Anavex Life Sciences’ experimental, once-daily pill blarcamesine, which is being tested in patients in the early stages of Alzheimer’s disease. This drug...
Communicating Innovation Without Creating Regulatory or Commercial Risk
Biotech companies today face a delicate balancing act: communicating innovation early enough to build credibility and momentum, while avoiding regulatory and commercial risks that can undermine long-term value. This tension is most evident in how companies talk about...
AI in Life Science Marketing: What’s Actually Working Beyond the Hype
Life science marketing teams are drowning in complexity. Regulatory compliance demands are tightening, scientific accuracy is non-negotiable, and sales cycles stretch 18-24 months or longer. Meanwhile, CMOs face relentless pressure to prove ROI faster while managing...
The Blind Men and the Elephant: A Parable for Modern Pain Management
Most of us have heard the ancient Indian and Buddhist parable “the blind men and the elephant.” Regardless of source, the parable usually contains these elements: A ruler assembles several blind men and brings an elephant before them. One feels the head and says the...
Innovate UK Awards Over £300k SMART Grant
Funding supports the co-design and roll-out of MEMORI, a Class IIb CE-certified SaMD platform, tailored to local clinical teams and systems MEMORI analyses multimodal clinical data in real-time to accurately predict the risk of hospital-acquired infections, alerting...
Re:Cognition Health & Cera to Expand Access to Alzheimer’s Trials
Re:Cognition Health, a global leader in brain and memory health research, and Cera, Europe’s largest digital-first home healthcare provider, today announce a new collaboration designed to expand access to Alzheimer’s and neurodegenerative clinical trials and support...
Biomanufacturing is the Next Industrial Revolution
Across the life sciences sector, a profound shift is underway. Biomanufacturing is poised to become a foundational pillar of how we will make things in the 21st century. Advances in bioreactor design, synthetic biology, and sustainable bioprocessing are enabling...
From Kennels to Clinics: Translating Veterinary Research to Human Trials
The next operational lessons for early-stage clinical trials in humans might not come from pharma but from a cattle ranch in Nebraska. While human clinical research debates decentralized trials, adaptive protocols, novel technologies, and new approaches to oversight,...
Statins Safer Than Previously Thought, Major Review Finds
Cholesterol-lowering drugs known as statins, taken by millions worldwide, are significantly safer than often perceived, according to a major new scientific analysis. Conducted by the Cholesterol Treatment Trialists’ (CTT) Collaboration and published in The Lancet, the...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.